Genmab — Juli 2024
-
-
-
Genmab: Nu er analytikerne begyndt at opjustere deres estimater for næste års overskud https://ugebrev.dk/flashnews/genmab-nu-er-analytikerne-begyndt-at-opjustere-deres-estimater-for-naeste-aars-overskud/?utm_source=ActiveCampaign&utm_medium=email&utm_content=Genmab%3A Nu er analytikerne begyndt at opjustere deres estimater for næste års overskud&utm_campaign=ØU Dagens Nyheder Middag - Investering (rettet 15%2F5-24)
-
Investeringspodcasten...#230: Novo Nordisk, Pandora, Genmab og A.P. Møller Mærsk https://proinvestor.com/boards/121296
-
Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves’ disease https://bmjopen.bmj.com/content/14/6/e079158
-
Godmorgen
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1183195/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Så er der stadig god "luft". "Genmab har fået snittet mere end 10 pct. af kursmålet af Barclays.
Finanshusets kursmål er nu på 2500 kr. mod før 2800 kr., og trods det lavere kursmål ser analytiker Emily Fields da fortsat et potentiale på 41,8 pct. i aktien i forhold til den aktuelle kurs. Den positive anbefaling "overvægt" gentages da også.
Genmab steg 0,3 pct. tirsdag til 1763,50 kr.
.\˙ MarketWire"
-
Epkinly Approved as Third-Line Treatment for Diffuse Large B-Cell Lymphoma in Korea
2024-07-10 https://kormedi.com/1704345/a-new-treatment-option-emerges-for-non-hodgkins-lymphoma/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind